Wall Street Zen Upgrades Biosig Technologies (NASDAQ:STEX) to "Hold"

Key Points

• Wall Street Zen upgraded Biosig Technologies (NASDAQ:STEX) from a "sell" to a "hold," while Weiss Ratings initiated coverage with a "sell (d-)" and the MarketBeat consensus remains a "Sell."
• Significant insider buying: insiders purchased 1,267,011 shares in the past 90 days (including CIO Mitchell Young Williams and Director Morgan Lee Lekstrom), and insiders now own 52.73% of the company.
• Shares opened at $1.21 with a market cap of $216 million, a 12‑month range of $0.40–$14.11 and a 50‑day SMA of $2.37; the company has a negative P/E of -0.90.

Biosig Technologies (NASDAQ:STEX - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings assumed coverage on Biosig Technologies in a report on Friday, January 23rd. They set a "sell (d-)" rating for the company. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of "Sell".

Biosig Technologies Stock Performance

Shares of NASDAQ:STEX opened at $1.21 on Friday. The company has a market cap of $216.01 million, a P/E ratio of -0.90 and a beta of 1.60. The firm's 50 day simple moving average is $2.37. Biosig Technologies has a twelve month low of $0.40 and a twelve month high of $14.11.

Insider Activity

In other news, CIO Mitchell Young Williams bought 51,511 shares of the firm's stock in a transaction that occurred on Friday, January 23rd. The shares were acquired at an average cost of $3.03 per share, with a total value of $156,078.33. Following the completion of the transaction, the executive directly owned 1,051,511 shares in the company, valued at $3,186,078.33. This represents a 5.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Morgan Lee Lekstrom purchased 41,000 shares of the stock in a transaction that occurred on Friday, January 23rd. The shares were purchased at an average price of $3.13 per share, for a total transaction of $128,330.00. Following the completion of the purchase, the director directly owned 48,000 shares of the company's stock, valued at approximately $150,240. This trade represents a 585.71% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders purchased 1,267,011 shares of company stock valued at $3,825,628. Insiders own 52.73% of the company's stock.

Biosig Technologies Company Profile

Biosig Technologies NASDAQ: STEX is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.